NVCR Stock Gains After Novocure Announces Positive Topline Results In Metastatic Pancreatic Cancer Therapy Trial

Novocure (NVCR) shares gained nearly 2% in Thursday’s pre-market trade after the company announced positive topline results in its metastatic pancreatic cancer therapy trial.

Novocure stated that PANOVA-4 met its pre-specified primary endpoint in the Phase 2 trial, achieving a statistically significant improvement in disease control rate. The PANOVA-4 study is a pilot, single-arm study of Tumor Treating Fields (TTFields) concomitant with atezolizumab, gemcitabine, and nab-paclitaxel as first-line treatment for metastatic pancreatic ductal adenocarcinoma (mPDAC).

Retail sentiment on Stocktwits around Novocure trended in the ‘neutral’ territory. NVCR was among the top trending tickers on the platform at the time of writing.

Get updates to this story developing directly on Stocktwits.

Also See: Trump Says Iran ‘Begging’ For Deal, Warns Them To 'Get Serious’ On Talks — Dow Futures Fall More Than 300 Points

For updates and corrections, email newsroom[at]stocktwits[dot]com.